Cargando…
Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults
A live attenuated zoster vaccine (ZOSTAVAX™, Merck & Co., Inc.) was approved by the Korea Ministry of Food and Drug Safety in 2009. However, the immunogenicity and safety of the vaccine has not been assessed in Korean population. This is multi-center, open-label, single-arm study performed with...
Autores principales: | Choi, Won Suk, Choi, Jung-Hyun, Choi, Jun Yong, Eom, Joong Sik, Kim, Sang Il, Pai, Hyunjoo, Peck, Kyong Ran, Sohn, Jang Wook, Cheong, Hee Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712571/ https://www.ncbi.nlm.nih.gov/pubmed/26770032 http://dx.doi.org/10.3346/jkms.2016.31.1.13 |
Ejemplares similares
-
Herpes zoster vaccine (Zostavax®): Cellulitic injection site reaction or bacterial cellulitis?
por: Cook, Ian F.
Publicado: (2016) -
Performance of Zoster Vaccine Live (Zostavax): A Systematic Review of 12 years of Experimental and Observational Evidence
por: Dooling, Kathleen, et al.
Publicado: (2017) -
Impact of Zostavax Vaccination on T-Cell Accumulation and Cutaneous Gene Expression in the Skin of Older Humans After Varicella Zoster Virus Antigen–Specific Challenge
por: Patel, Neil P, et al.
Publicado: (2018) -
Prognostic factors of severe sepsis: a result of Korean sepsis registry system
por: Chun, Byung-Chul, et al.
Publicado: (2008) -
Humoral and Cellular Immunogenicity of Zoster Vaccine within One Year after Herpes Zoster
por: Lee, Eunyoung, et al.
Publicado: (2017)